These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 22285549)
1. The development of encapsulated cell technologies as therapies for neurological and sensory diseases. Zanin MP; Pettingill LN; Harvey AR; Emerich DF; Thanos CG; Shepherd RK J Control Release; 2012 May; 160(1):3-13. PubMed ID: 22285549 [TBL] [Abstract][Full Text] [Related]
2. [Nerve growth factor in neurodegeneration and neurorestorative therapy]. Lorigados-Pedre L; Bergado-Rosado J Rev Neurol; 2004 May 16-31; 38(10):957-71. PubMed ID: 15175980 [TBL] [Abstract][Full Text] [Related]
3. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies. Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S Nanomedicine (Lond); 2014 Apr; 9(5):709-22. PubMed ID: 24827845 [TBL] [Abstract][Full Text] [Related]
4. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Barchet TM; Amiji MM Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842 [TBL] [Abstract][Full Text] [Related]
5. Update on immunoisolation cell therapy for CNS diseases. Emerich DF; Salzberg HC Cell Transplant; 2001; 10(1):3-24. PubMed ID: 11294469 [TBL] [Abstract][Full Text] [Related]
7. Encapsulated cell therapy for neurodegenerative diseases: from promise to product. Emerich DF; Orive G; Thanos C; Tornoe J; Wahlberg LU Adv Drug Deliv Rev; 2014 Apr; 67-68():131-41. PubMed ID: 23880505 [TBL] [Abstract][Full Text] [Related]
8. Neurotrophic factors and neurodegenerative diseases: a delivery issue. Ruozi B; Belletti D; Bondioli L; De Vita A; Forni F; Vandelli MA; Tosi G Int Rev Neurobiol; 2012; 102():207-47. PubMed ID: 22748832 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Popovic N; Brundin P Int J Pharm; 2006 May; 314(2):120-6. PubMed ID: 16529886 [TBL] [Abstract][Full Text] [Related]
11. [Cell encapsulation for the treatment of central nervous system disorders]. Portero A; Orive G; Hernández RM; Pedraz JL Rev Neurol; 2010 Apr; 50(7):409-19. PubMed ID: 20387211 [TBL] [Abstract][Full Text] [Related]
12. Ubiquitin proteasome system as a pharmacological target in neurodegeneration. Hol EM; Fischer DF; Ovaa H; Scheper W Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921 [TBL] [Abstract][Full Text] [Related]
13. Cell microencapsulation technology: towards clinical application. Murua A; Portero A; Orive G; Hernández RM; de Castro M; Pedraz JL J Control Release; 2008 Dec; 132(2):76-83. PubMed ID: 18789985 [TBL] [Abstract][Full Text] [Related]
14. A cell encapsulation device for studying soluble factor release from cells transplanted in the rat brain. Kim YT; Hitchcock R; Broadhead KW; Messina DJ; Tresco PA J Control Release; 2005 Jan; 102(1):101-11. PubMed ID: 15653137 [TBL] [Abstract][Full Text] [Related]
15. CRIB (NGF delivery) Cyto Therapeutics Inc. Cockett MI IDrugs; 1998 Jul; 1(3):362-7. PubMed ID: 18465562 [TBL] [Abstract][Full Text] [Related]
16. Cell microencapsulation technology for biomedical purposes: novel insights and challenges. Orive G; Gascón AR; Hernández RM; Igartua M; Luis Pedraz J Trends Pharmacol Sci; 2003 May; 24(5):207-10. PubMed ID: 12767713 [TBL] [Abstract][Full Text] [Related]
17. Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma. Skinner SJ; Geaney MS; Lin H; Muzina M; Anal AK; Elliott RB; Tan PL J Neural Eng; 2009 Dec; 6(6):065001. PubMed ID: 19850973 [TBL] [Abstract][Full Text] [Related]
18. [Neurotrophic factors: basis for their clinical application]. Morís G; Vega JA Neurologia; 2003; 18(1):18-28. PubMed ID: 12590377 [TBL] [Abstract][Full Text] [Related]
19. Immunoisolation cell therapy for CNS diseases. Emerich DF; Winn SR Crit Rev Ther Drug Carrier Syst; 2001; 18(3):265-98. PubMed ID: 11442201 [TBL] [Abstract][Full Text] [Related]